sb 203580 has been researched along with temocapril hydrochloride in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (temocapril hydrochloride) | Trials (temocapril hydrochloride) | Recent Studies (post-2010) (temocapril hydrochloride) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 154 | 32 | 15 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akishita, M; Hasegawa, H; Kozaki, K; Nagai, K; Sudoh, N; Toba, K; Xi, H; Yu, W | 1 |
1 other study(ies) available for sb 203580 and temocapril hydrochloride
Article | Year |
---|---|
Angiotensin converting enzyme inhibitor attenuates oxidative stress-induced endothelial cell apoptosis via p38 MAP kinase inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Cattle; Cells, Cultured; DNA Fragmentation; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Inhibitors; Hydrogen Peroxide; Imidazoles; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyridines; Thiazepines; Tumor Necrosis Factor-alpha | 2006 |